Th1, Th2 and Th3 cytokines in the pathogenesis of bullous pemphigoid-Reference-Cited by-同舟云学术

Th1, Th2 and Th3 cytokines in the pathogenesis of bullous pemphigoid

Published:2002-11 Issue:2 Volume:30 Page:116-128
ISSN:0923-1811
Container-title:Journal of Dermatological Science
language:en
Short-container-title:Journal of Dermatological Science

Author:

Giomi Barbara,Caproni Marzia,Calzolari Anna,Bianchi Beatrice,Fabbri Paolo

Publisher

Elsevier BV

Subject

Dermatology,Molecular Biology,Biochemistry

Reference35 articles.

1. The pathogenic mechanisms of blister formation in bullous pemphigoid;Naito;J. Invest. Dermatol.,1982

2. Experimental bullous pemphigoid in guinea pigs: the role of pemphigoid antibodies, complement and migrating cells;Naito;J. Invest. Dermatol.,1984

3. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls;Budinger;J. Clin. Invest.,1998

4. Humoral and cellular autoimmunity in autoimmune bullous skin disorders;Hertl;Int. Arch. Allergy Imunol.,2000

5. In vitro proliferative responses and antibody titres specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to MHC class II genes;Brocke;J. Clin. Invest.,1900

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-cell transcriptomics analysis of bullous pemphigoid unveils immune-stromal crosstalk in type 2 inflammatory disease;Nature Communications;2024-07-15

2. Association of Dipeptidiyl Peptidase-4 Inhibitors and Bullose Pemphigoid: A Report of Four Cases;Medeniyet Medical Journal;2024-06-28

3. Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update;American Journal of Clinical Dermatology;2023-12-29

4. Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches;Clinical Reviews in Allergy & Immunology;2023-10-28

5. Immune cells in pemphigus vulgaris and bullous Pemphigoid: From pathogenic roles to targeting therapies;International Immunopharmacology;2023-10